Show simple item record

dc.contributor.authorJones, Hannah F.
dc.contributor.authorAdams, Clive E.
dc.date.accessioned2017-09-20T15:57:48Z
dc.date.available2017-09-20T15:57:48Z
dc.date.issued2010
dc.identifier.citationAhmed, U., Jones, H. F. & Adams, C. E. (2010). Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews, (4), pp.1-27.
dc.identifier.other10.1002/14651858.CD007445.pub2
dc.identifier.urihttp://hdl.handle.net/20.500.12904/10026
dc.description.abstractBackground Agitated or violent behaviour constitutes 10% of all emergency psychiatric treatment. Some guidelines do not recommend the use of chlorpromazine for rapid tranquillisation but it is still often used for this purpose. Objectives To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression. Search strategy We searched the Cochrane Schizophrenia Group Trials Register (up to July 2009) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. Selection criteria Randomised control trials or double blind trials (implying randomisation) comparing chlorpromazine with another drug or placebo for people who are thought to be acutely aggressive or agitated due to psychotic illness. Data collection and analysis We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a fixed-effects model. Main results One study (total n=30) met the inclusion criteria. When compared with haloperidol (Man 1973) (1 RCT, n=30) people allocated chlorpromazine were no more likely to have one additional injection than those allocated haloperidol (RR 3.00 CI 0.13 to 68.26). This remained true for 2-4 injections (RR 0.90 CI 0.52 to 1.55) and for 5 or more injections (RR 0.75 CI 0.20 to 2.79). Two people allocated chlorpromazine had sudden, serious hypotension while no one allocated haloperidol had such an effect (RR 5.00 CI 0.26 to 96.13). No extrapyramidal symptoms were observed. One person allocated chlorpromazine developed status epilepticus (RR 3.00 CI 0.13 to 68.26). Authors' conclusions Overall the quality of evidence is limited, poor and dated. Where drugs that have been better evaluated are available, it may be best to avoid use of chlorpromazine. Where chlorpromazine is used for acute aggression or where choices are limited, relevant trials are possible and urgently needed.
dc.description.urihttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007445.pub2/full
dc.formatFull text uploaded
dc.subjectDrug therapy
dc.subjectPsychotic disorders
dc.subjectAggression
dc.titleChlorpromazine for psychosis induced aggression or agitation
dc.typeArticle
refterms.dateFOA2021-06-14T11:08:28Z
html.description.abstractBackground Agitated or violent behaviour constitutes 10% of all emergency psychiatric treatment. Some guidelines do not recommend the use of chlorpromazine for rapid tranquillisation but it is still often used for this purpose. Objectives To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression. Search strategy We searched the Cochrane Schizophrenia Group Trials Register (up to July 2009) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. Selection criteria Randomised control trials or double blind trials (implying randomisation) comparing chlorpromazine with another drug or placebo for people who are thought to be acutely aggressive or agitated due to psychotic illness. Data collection and analysis We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a fixed-effects model. Main results One study (total n=30) met the inclusion criteria. When compared with haloperidol (Man 1973) (1 RCT, n=30) people allocated chlorpromazine were no more likely to have one additional injection than those allocated haloperidol (RR 3.00 CI 0.13 to 68.26). This remained true for 2-4 injections (RR 0.90 CI 0.52 to 1.55) and for 5 or more injections (RR 0.75 CI 0.20 to 2.79). Two people allocated chlorpromazine had sudden, serious hypotension while no one allocated haloperidol had such an effect (RR 5.00 CI 0.26 to 96.13). No extrapyramidal symptoms were observed. One person allocated chlorpromazine developed status epilepticus (RR 3.00 CI 0.13 to 68.26). Authors' conclusions Overall the quality of evidence is limited, poor and dated. Where drugs that have been better evaluated are available, it may be best to avoid use of chlorpromazine. Where chlorpromazine is used for acute aggression or where choices are limited, relevant trials are possible and urgently needed.


Files in this item

Thumbnail
Name:
Ahmed 2010 1-27.pdf
Size:
309.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record